Clinic-based treatment of childhood overweight and obesity continues to fail to meet the burden of that condition. 1 Childhood overweight and obesity has reached epidemic proportions in the United States, with recent estimates of 32% for children aged 2-19 years. 2 Together, pediatric overweight and obesity increase the risk of several short-term comorbidities including dyslipidemia, hypertension, insulin resistance, abnormal glucose tolerance, sleep apnea, and orthopedic complications. 3 A recent systematic review demonstrates the long-term consequences of overweight and obesity and shows that overweight and obese children experience significantly increased risk in their adult life of premature death, diabetes, hypertension, ischemic heart disease, stroke, asthma, and polycystic ovary syndrome. 4 In addition to the aforementioned physical consequences of childhood obesity, overweight and obese children may experience discrimination that can lead to low self-esteem, eating disorders, and other mental health conditions. 3 These health consequences of childhood overweight and obesity, combined with the high prevalence of the condition, indicate the necessity for adequate diagnosis and treatment.
The American Academy of Pediatrics (AAP) convened an expert committee to develop clinical guidelines for best practices to identify and treat childhood overweight and obesity informed by the Chronic Care Model. 5, 6 These guidelines have been available since 1998 and were updated in 2007. Several studies, however, have found that pediatricians continue to underdiagnose and unsuccessfully manage weight problems in children. [7] [8] [9] [10] Identified barriers to guideline adherence by pediatricians include low self-efficacy in treatment as a result of the complex biological and social etiology of the disease, lack of a proven treatment strategy, insufficient training programs, low financial reimbursement, and lack of onsite support staff (e.g., dietitians). [11] [12] [13] [14] Evidence suggests that proximity to a dietitian or nutritional counselor significantly affects physician rates of referral to those services, and that decreased access to special health-care services could account for some of the lack of physician referrals. 15 Despite recognition of these issues, limited data exist on clinic-based interventions that promote the effective diagnosis and treatment of pediatric overweight and obesity.
The 215-GO! program, which was developed in 2004 in response to issues concerning childhood overweight and obesity, represents an interdisciplinary approach to treating the disease. 215-GO! is an acronym: 2 5 limit screen time to ,2 hours a day; 1 5 include a minimum of one hour per day of physical activity; 5 5 eat five servings of fruit and vegetables per day; G 5 great; and O 5 opportunities. The program runs in four of the Philadelphia Department of Public Health (PDPH)-operated health centers (HCs) that provide care without regard to ability to pay and serve predominantly low-income and minority populations. Estimates from 2003 revealed an obesity and overweight prevalence rate of 34% for children who attend the HCs. 16 All physicians at participating 215-GO! clinics participated in a daylong obesity summit convened by the Philadelphia Health Commissioner that focused on childhood obesity treatment and prevention strategies. Physicians also received ongoing continuing medical education to remain apprised of new childhood obesity treatment protocols and guidelines. The 215-GO! program provides counseling by a nutritionist and a health educator to overweight and obese HC patients. Children are referred to the program staff by their pediatricians, and this team of practitioners led by the pediatrician develops a coordinated treatment plan. Thus, the program alters the organizational environment of the HC by providing comprehensive disease management between a child's physician and an onsite nutritionist and health educator.
We viewed this program within the framework of the Donabedian structure-process-outcome model for assessing quality of care and considered 215-GO! a structural element. 17 We hypothesized that the novel structural element would lead to an improvement in the processes of care for the overweight and obese children it is designed to help. Likewise, we predicted that the use of an interdisciplinary team would lead to greater reductions in body mass index (BMI) percentile for those children.
MetHoDS

Study design and setting
We conducted a retrospective cohort study by reviewing medical charts at six of the Philadelphia HCs. Four of these HCs offer the 215-GO! pediatric obesity treatment program. The two control HCs do not offer any specialized interdisciplinary overweight or obesity management programs.
Subjects
Pediatric patients aged 3-18 years who had a well-child visit at any of the six HCs from July 1, 2007, to June 30, 2008; a BMI $85th percentile rank (PR); and a followup visit at least six months after the initial visit with a recorded height and weight at both visits were eligible for this study. Pregnant girls were excluded from the study. Patient charts were screened to identify patients who met eligibility criteria. Charts were selected for screening by randomizing medical record numbers (MRNs) of children who had an initial well-child visit index date from July 1, 2007, to June 30, 2008 . MRNs of these children were identified from the PDPH Management Information System. Patients with a BMI $95th PR at the index visit were categorized as obese, and patients with a BMI $85th PR but ,95th PR were categorized as overweight, as per AAP guidelines. 5 Patients at HCs with 215-GO! clinics were divided into 215-GO! (the 215-GO! group) and non-215-GO! (controls at the 215-GO! HCs group) patient groups; patients from HCs without a 215-GO! program formed a third patient group (controls at the non-215-GO! HCs group). At each HC, the first 30 eligible patient charts identified from each patient group underwent further review to extract demographic, clinical, and quality-of-care data. Control patients were defined as having never been seen by 215-GO! staff. 215-GO! patients were defined as having at least one visit with a pediatrician and a 215-GO! health educator or nutritionist.
Outcomes
Process-of-care indicators were informed by the AAP guidelines and included blood pressure (BP) recorded, BMI recorded, BMI plotted, and diagnosis in the chart at the date of the index visit. BP was recorded as taken if the value was noted in the chart. BMI recording was counted if either the BMI value or BMI percentile was noted. BMI plot was counted if the child's BMI was plotted on a Centers for Disease Control and Prevention gender-specific BMI graph for the child's age at the index visit. Diagnosis was counted as having been recorded if any diagnosis of overweight or obese was listed in the chart. Laboratory test results included lipid profile, liver enzymes, and glucose test. Lipid profile was defined as at least including values for both lowdensity lipoprotein and high-density lipoprotein, or as total cholesterol alone. Liver enzyme test was defined as including values for both aspartate aminotransferase and alanine aminotransferase. Glucose tests were required to have been determined from blood rather than urine tests, but included random or fasting glucose tests. Laboratory tests were counted as conducted if they occurred within a year before or 90 days after the index visit, because laboratories are not routinely repeated within this time frame.
Analysis
All analyses were conducted using Stata ® version 12.1. 18 We calculated summary statistics for continuous characteristics using an analysis of variance F-test, and we used the global Chi-square statistic from a logistic model for binary characteristics. We used a multilevel logistic regression model to evaluate adjusted odds ratios (AORs) for all process-of-care measures because this model provides robust standard error (SE) estimates by accounting for the correlation effect present in multilevel settings that involve subject clustering (i.e., HC). The multilevel model used HC as a cluster effect and included the covariates-patient group (215-GO!, controls at 215-GO! HCs, and controls at non-215-GO! HCs), sex (male), age in years, BMI category (obese), and race variables of white/other, Asian, and Hispanic, with non-Hispanic black people as the reference group-to calculate AORs.
We analyzed BMI change by subtracting the BMI z-score at the return visit from the BMI z-score at the initial visit. A reduction in age-and gender-specific BMI is therefore represented as a positive coefficient value. A multilevel linear regression model with robust SEs was fit on the BMI z-score change and used HC as a cluster effect. Model covariates included patient group (215-GO!, controls at 215-GO! HCs, and controls at non-215-GO! HCs), sex (male), age in years, BMI category (obese), follow-up time, and race variables of white/other, Asian, and Hispanic, with non-Hispanic black people as the reference group.
reSultS
Characteristics of the study population are shown in Table 1 . Controls were divided into two groups: controls at HCs that offer a 215-GO! program and controls at HCs that do not offer a 215-GO! program. A total of 295 patients were identified as eligible for this study based on the criteria outlined previously. Of the 295 patients, 59 (20%) were control patients from non-215-GO! HCs, 119 (40%) were control patients from 215-GO! HCs, and 117 (40%) were 215-GO! patients. Overall, 135 (46%) patients were male and 160 (54%) patients were female; as such, there was no significant difference in the gender distribution among the three groups. The majority of patients were non-Hispanic black (66%), and there were significant differences in the racial composition of the groups, as shown in Table  1 . No differences were observed in age at initial visit or mean follow-up time among the groups. A significantly greater portion of the 215-GO! subjects (83%) than the controls at either the non-215-GO! HCs (49%) or the 215-GO! HCs (46%) were obese (p,0.001). Table 2 shows the naïve analysis of process-of-care indicators, indicating a difference among the three groups for BMI recording (p,0.001), BMI plotting (p,0.05), and diagnosis in the chart (p,0.001). Table 4 . AORs revealed no significant differences between either 215-GO! patients and controls at 215-GO! HCs, or between controls at 215-GO! HCs and controls at non-215-GO! HCs. A year increase in age increased the likelihood of having a lipid (AOR51.28, 95% CI 1.16, 1.40), liver (AOR51.24, 95% CI 1.10, 1.40), or glucose (AOR51.29, 95% 1.17, 1.42) test.
Overall, 62% of the entire study population was found to decrease their age-and gender-specific BMI z-score, including 56% of the 215-GO! patients, 66% of controls at 215-GO! HCs, and 66% of controls at non-215-GO! HCs. Results from a multilevel, multivariate model controlling for the correlation among individuals within the same HC are presented in Table  5 . Adjusted parameter estimates from this model show that 215-GO! participants increased their BMI z-score compared with control patients at 215-GO! HCs (b5-0.201, SE50.042, p,0.001). Controls at non-215-GO! HCs decreased their BMI percentile (b50.092, SE50.049, p,0.05) compared with controls 
DiScuSSion
This analysis of the clinic-based 215-GO! pediatric obesity treatment program in the PDPH HCs framed this intervention as a structural change that would lead to process-of-care improvements following Donabedian's structure-process-outcome model. In turn, these process improvements should lead to improved patient outcomes. This analysis showed improved processes of care that correspond to clinical recommendations but not to improved patient BMI outcomes. These results suggest that the 215-GO! program improves most processes of care, but these improvements in processes of care are not translating into improved BMI outcomes for all patients.
An interesting result of this study was the observation that controls at 215-GO! HCs did not experience improvements in processes of care compared with controls at non-215-GO! HCs, even though the same physicians were treating both 215-GO! and non-215-GO! patients. Non-215-GO! patients treated by physicians who received obesity management training and who also treat 215-GO! patients should deliver improved quality of care to all patients, yet this heightened quality of care was not observed. An explanation of this anomaly is that the training alone is insufficient to improve a pediatrician's efficacy of treatment and needs to be combined with the willingness of a child and the child's parents to attend the 215-GO! counseling sessions. 11, 19, 20 Previous literature has suggested that parental involvement can increase the monitoring and evaluation of obese children. 20, 21 The parent-physician relationship may help physicians overcome barriers to treatment and can be critical in achieving BMI reductions. Future research should examine physicians' attitudes toward treating overweight and obese children in response to family involvement.
Other clinical interventions aimed at improving processes of care for overweight and obese children have shown success using similar approaches to the 215-GO! program, including collaboration among physicians, nurses, nutritionists, and other ancillary staff in developing a child's treatment plan. [21] [22] [23] [24] Physician and staff training in these programs also involves education and awareness of the AAP guidelines, screening techniques, and counseling strategies. [21] [22] [23] [24] [25] Similarly, interventions involving the use of electronic medical records (EMRs) have proven successful in improving guideline adherence in physicians treating pediatric overweight and obesity. [25] [26] [27] [28] The PDPH clinics are in the process of implementing an EMR system, which could further improve processes of care for all children.
Despite this growing body of evidence that outlines different care delivery designs that support improved processes of care, few studies also report BMI changes from clinic-based interventions. 29 Furthermore, studies that do report BMI changes have yet to show BMI decreases. 30, 31 Lack of a decrease in BMI could be due to several factors, including the complex etiology of overweight and obesity as well as insufficient training and proven treatment strategies. [12] [13] [14] A recent systematic review of obesity prevention programs examined the comparative effectiveness of school, home, community, and primary care programs, as well as the combina- 
Limitations
This study had two major limitations. A selection bias was present in the distribution of obese patients in the control vs. 215-GO! groups. Regression models employed in this study controlled for obese status, and model results were validated with a propensity score matching approach. However, underlying differences between 215-GO! patients and controls could have biased results. For example, severely obese patients may be easier to visually diagnose and, therefore, more likely to be referred to the 215-GO! clinic. Also, severely obese patients may have been referred several times to the 215-GO! clinic, yet only when the individual becomes motivated enough by his/her weight gain does he/ she attend the 215-GO! clinic. This study also did not account for the weight gain trajectory of patients, and data limitations would make that assessment difficult. Understanding the weight gain trajectory of patients would help determine the effect of these biases, as obese children actively gaining weight may reduce the effect of the program and may account for the observed increase in BMI for treated patients. Alternatively, motivated obese children may be more apt to lose weight and, thus, lead to an overestimation of the program. Future studies should examine the pattern of weight loss in obese patients.
A second major limitation of this study was a result of the low frequency of laboratory tests. Low frequency of an outcome can bias results from the multilevel model. It should be noted that the PDPH HCs examined in this study had laboratory results recorded slightly more frequently than those observed in other studies, yet laboratory tests were still infrequently conducted. [8] [9] [10] Additionally, the guidelines for appropriate laboratory tests by the AAP expert committee and an endocrine expert committee suggest that laboratory tests be taken for children .10 years of age depending on BMI percentile and the presence of additional risk factors. 5, 32 Again, restricting the analysis to children .10 years of age in this study sample reduced the power of the study and the frequency of laboratory tests. PDPH guidelines for appropriate laboratory tests depend largely on the identification and evaluation of family history and complications. This study did not examine the identification of family history and complications; as such, it failed to possess the ability to determine appropriate laboratory tests based on that definition. Also, PDPH guidelines do not specify the proper frequency of laboratory tests for children of any age. Simplification of clinical guidelines regarding laboratory tests may improve physicians' ability to adhere to guidelines.
concluSion Childhood overweight and obesity has reached epidemic proportions in the U.S., yet there is a dearth of evidence for effective clinic-based programs to both identify and treat the condition. This study provides an alternative model that promotes improved processes of care in an urban setting. However, the 215-GO! program remains insufficient on its own to reduce BMI for all children. Improvements in processes of care are necessary to begin to identify and develop treatment protocols for overweight and obesity. Proper identification and recording of the condition can assist program designers in assessing the needs of the community. Additionally, improved processes of care will allow physicians to better evaluate their patients and identify risk factors for comorbidities. Supporting clinic-based programs with community, school, and policy-level interventions can help to translate the observed processes of care into improved outcomes. Future research should examine how the impact of multilevel programs will help in the development of effective treatment protocols.
